Niagen Bioscience/$NAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
104
ISIN
US1710774076
Website
NAGE Metrics
BasicAdvanced
$1.1B
74.93
$0.18
2.08
-
Price and volume
Market cap
$1.1B
Beta
2.08
52-week high
$14.49
52-week low
$2.31
Average daily volume
935K
Financial strength
Current ratio
3.658
Quick ratio
3.043
Long term debt to equity
4.654
Total debt to equity
6.367
Profitability
EBITDA (TTM)
14.022
Gross margin (TTM)
62.51%
Net profit margin (TTM)
13.07%
Operating margin (TTM)
12.26%
Effective tax rate (TTM)
3.24%
Revenue per employee (TTM)
$1,040,000
Management effectiveness
Return on assets (TTM)
12.21%
Return on equity (TTM)
33.47%
Valuation
Price to earnings (TTM)
74.93
Price to revenue (TTM)
9.515
Price to book
19.04
Price to tangible book (TTM)
19.16
Price to free cash flow (TTM)
52.544
Free cash flow yield (TTM)
1.90%
Free cash flow per share (TTM)
25.52%
Growth
Revenue change (TTM)
29.77%
Earnings per share change (TTM)
-427.85%
3-year revenue growth (CAGR)
15.51%
10-year revenue growth (CAGR)
19.95%
3-year earnings per share growth (CAGR)
-23.70%
10-year earnings per share growth (CAGR)
3.28%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
Bulls say / Bears say
Niagen Bioscience reported a 38% year-over-year increase in Q1 2025 net sales to $30.5 million, driven by strong demand for its Tru Niagen® and Niagen® ingredient products. (tipranks.com)
H.C. Wainwright reaffirmed its Buy rating on Niagen Bioscience with a price target of $11.00, citing the company's resilience amid global tariffs and strong financial position. (investing.com)
The company expanded its intellectual property portfolio by securing a new U.S. patent for various nicotinamide riboside salts, providing exclusive rights until 2034 and enhancing its competitive edge. (investing.com)
Despite strong revenue growth, Niagen Bioscience's stock has experienced significant volatility, with a 71.9% surge over the past six months but an 18.2% decline in the past week, indicating potential instability. (investing.com)
The company's rebranding from ChromaDex Corp. to Niagen Bioscience may lead to temporary market confusion and require additional marketing expenses to establish brand recognition. (investing.com)
While Niagen Bioscience has a strong financial position, its reliance on a single manufacturing partner, W.R. Grace, could pose supply chain risks if any disruptions occur. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
NAGE News
AllArticlesVideos
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
Business Wire·6 days ago
Niagen Bioscience to Participate in the BIO 2025 International Convention
Business Wire·2 weeks ago
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Niagen Bioscience stock?
Niagen Bioscience (NAGE) has a market cap of $1.1B as of June 26, 2025.
What is the P/E ratio for Niagen Bioscience stock?
The price to earnings (P/E) ratio for Niagen Bioscience (NAGE) stock is 74.93 as of June 26, 2025.
Does Niagen Bioscience stock pay dividends?
No, Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Niagen Bioscience dividend payment date?
Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Niagen Bioscience?
Niagen Bioscience (NAGE) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.